TY - JOUR T1 - SARSeq, a robust and highly multiplexed NGS assay for parallel detection of SARS-CoV2 and other respiratory infections JF - medRxiv DO - 10.1101/2020.10.28.20217778 SP - 2020.10.28.20217778 AU - Ramesh Yelagandula AU - Aleksandr Bykov AU - Alexander Vogt AU - Robert Heinen AU - Ezgi Özkan AU - Marcus Martin Strobl AU - Juliane Christina Baar AU - Kristina Uzunova AU - Bence Hajdusits AU - Darja Kordic AU - Erna Suljic AU - Amina Kurtovic-Kozaric AU - Sebija Izetbegovic AU - Justine Schaefer AU - Peter Hufnagl AU - Alexander Zoufaly AU - Tamara Seitz AU - VCDI AU - Manuela Födinger AU - Franz Allerberger AU - Alexander Stark AU - Luisa Cochella AU - Ulrich Elling Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/03/2020.10.28.20217778.abstract N2 - During a pandemic, mitigation as well as protection of system-critical or vulnerable institutions requires massively parallel, yet cost-effective testing to monitor the spread of agents such as the current SARS-CoV2 virus. Here we present SARSeq, saliva analysis by RNA sequencing, as an approach to monitor presence of SARS-CoV2 and other respiratory viruses performed on tens of thousands of samples in parallel. SARSeq is based on next generation sequencing of multiple amplicons generated in parallel in a multiplexed RT-PCR reaction. It relies on a two-dimensional unique dual indexing strategy using four indices in total, for unambiguous and scalable assignment of reads to individual samples. We calibrated this method using dilutions of synthetic RNA and virions to show sensitivity down to a few molecules, and applied it to hundreds of patient samples validating robust performance across various sample types. Double blinded benchmarking to gold-standard quantitative RT-PCR performed in a clinical setting and a human diagnostics laboratory showed robust performance up to a Ct of 36. The false positive rate, likely due to cross contamination during sample pipetting, was estimated at 0.04-0.1%. In addition to SARS-CoV2, SARSeq detects Influenza A and B viruses as well as human rhinovirus and can be easily expanded to include detection of other pathogens. In sum, SARSeq is an ideal platform for differential diagnostic of respiratory diseases at a scale, as is required during a pandemic.Competing Interest StatementTo protect methods developed herein being blocked through third party IP as well as enable roll-outs towards society needs, a priority-establishing European patent application was filed on Oct. 19., 2020. We will, however, grant non-exclusive licenses for all non-commercial use. U.E. consults to Tango Therapeutics and is a co-founder of JLP Health.Clinical Trialno clinical trialFunding StatementCuriosity driven biomedical research at the IMP is largely sponsored by Boehringer Ingelheim. IMBA is generously funded by the OEAW.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study includes preliminary investigations and results of a clinical performance study approved by the local Ethic Committee of Vienna (#EK 20-208-0920). For that, left-over samples from healthy participants were obtained from an anonymous routine SARS-CoV2 screening pipeline, and left-over patient samples in Fig. 5G,H were obtained by the Austrian Agency for Health and Food Safety (AGES) in a diagnostic pipeline and provided to us fully anonymized. For VTM samples used for Figure 5 A-F, an additional approval (#06-04-9-33163 from 21/07/2020) was obtained from the Ethics Committee of the Clinical Center of the University of Sarajevo. The study was conducted in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis script is available on GitHub at https://github.com/alex-stark-imp/SARSeq and at https://starklab.org. https://github.com/alex-stark-imp/SARSeq ER -